WAVEIMPLANT, a young innovative company developing ImplantUS, a medical device for measuring the stability of dental implants and securing associated surgical procedures, was elected among the 3 best French start-ups in the MedTech sector by an international jury of investors gathered as part of the Tech Tour France 2021 organized digitally on April 20 and 21, 2021.
Encouraged by CNRS Innovation to participate in this event under the auspices of Bpifrance and with the partnerships of French innovation valuation-involved organizations SATT, CEA, CNRS, IFPEN, Inria, Inserm-Transfert, INRAE Transfert and PSL University, WaveImplant presented its development, certification, marketing, financing and growth project to an international audience of venture capital investors (institutional, Corporate, Family Offices, and Business Angels) from all over Europe. Out of 78 companies applying and 40 invited to compete, only 10 of them were winners of the award. WaveImplant is one of them. In addition, in January or February 2022, WaveImplant will be invited to present its project to a panel of investors from Europe, Asia and North America.
Pascal Breton, CEO of WAVEIMPLANT, declares: “First of all, we would like to thank the entire CNRS Innovation team for the confidence they place in us every day and for the unwavering support they give us. Very clearly, CNRS Innovation pushed us to participate in this Tech Tour France 2021. Of course, I am extremely happy with our success which, in this period of active fundraising, brings us additional recognition, notoriety, and visibility in France, but also in Europe”.
WAVEIMPLANT, a French Medtech start-up specializing in the development and marketing of decision support medical devices, particularly in the field of dental implantology, is focusing on the development of ImplantUS, a new ultrasound medical device resulting from the research work of the team of Guillaume Haïat PhD, within the Laboratoire Modélisation et Simulation Multi-Echelle (MSME, UMR CNRS 8208, Créteil, France). ImplantUS provides a better framework for the increasingly widespread dental implantology surgical procedures and better guarantees their success in the short, medium, and long terms.
Today, statistical analysis shows that 10 to 20% of implant placement surgical procedures fail (see the publication by Ji et al., J.Oral Implant., 2012), which is obviously highly detrimental to patients and to dental surgeons. The vast majority of these failures are the result of an insufficient osseointegration of the implant and of a lack of its stability. Thus, before loading the implant with the prosthesis, practitioners are looking for an accurate and reliable assessment of its stability. However, the empirical or technological approaches currently used for this purpose do not meet the required specifications in terms of sensitivity and reproducibility and leave a clear unmet medical need that ImplantUS will satisfy.
Founded in May 2019, WAVEIMPLANT operates a portfolio of intellectual property licensed from the CNRS exclusively and worldwide, in all fields of application. WAVEIMPLANT is based on a solid, and reliable technology, perfectly validated in vitro, ex vivo, in vivo and in silico,
which will allow it to offer its first decision support medical device (i.e. ImplantUS) from 2023.
Beyond its affiliation with Atlanpole and Atlanpole Biothérapies (Nantes, France), WAVEIMPLANT is supported by Descartes Incubator and is a member of the Medicen and Cap Digital clusters (Paris, France). WAVEIMPLANT is currently engaged in a crowdfunding operation in partnership with Happy Capital.
Learn more: https://fr.waveimplant.com
WAVEIMPLANT – Pascal Breton, CEO
Tel.: +33 (0)6 82 65 47 69
Address: 12 avenue Carnot, 44000 Nantes